[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].

Abstract excerpt

The Philadelphia-negative chronic myeloproliferative disorders feature autonomous myeloid hyperproliferation and hypersensitivity to a number of growth factors, which most recently have been shown to be explained by a guanine-to-thymidine mutation in the Janus tyrosine kinase (JAK2) gene, implicating that phenylalanine is substituted with valine in position 617 (V617F mutation). JAK2 is of particular importance...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Janus Kinase 2
• Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive